This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Q3 to Sep 2026 revenue Rs 536.17 crore versus Rs 547.04 crore; Mehsana sale by year-end
VESUVIUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 2.5 pts less than its Electrodes & Refractories peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone Q3 to September 30, 2026: revenue from operations was Rs 536.17 crore versus Rs 547.04 crore in Q3 2025; profit after tax was Rs 58.51 crore versus Rs 61.54 crore. Standalone nine-month revenue was Rs 1,553.56 crore versus Rs 2,104.33 crore; profit after tax was Rs 183.85 crore versus Rs 264.08 crore. Auditors gave an unmodified opinion. Mehsana plant sale to Foseco India is expected by year-end; gain will be booked on completion.
Q3 revenue fell about 2% and profit after tax about 5%, which may weigh on the stock; any Mehsana sale gain comes only after completion.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹566.8 Cr | ₹547.0 Cr | +3.6% |
| Operating profit | ₹69.04 Cr | ₹75.46 Cr | −8.5% |
| Profit after tax | ₹57.10 Cr | ₹61.54 Cr | −7.2% |
| EBITDA margin | 15.5% | 16.9% | −1.4 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.